Cardiome Pharma (CRME) Slips onLab Results

Cardiome Pharma Corp. CRME shares dipped 1.6% to $4.86 today announced the publication of results from an open label, single-center, single-arm study conducted by independent researchers at the Hospital Arnau de Vilanova in Valencia, Spain, with the objective of reporting their experience of using BRINAVESS® in atrial fibrillation patients eligible to receive the drug in the emergency department setting between Jan 2014 to Dec 2015. Share volume totaled 2,000, compared to an all-day average of 40,000